PFE Pfizer Inc.
Pfizer Inc. (PFE) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 4 comparable calls have settled; 0% reached the published sell target. Information only, not financial advice.
Mid-channel (provisional)
Price is between the two trend lines. Nothing to act on yet.
Read from the last 2 years of history we hold: rising, drifting +8% a year. The nearest ceiling overhead is US$28.90. What would overturn this: a close below US$26.49 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 2 years read from
- US$26.49 – US$28.90 Rising channel, +8% a year
- Position in that channel
- 41% 0% at the floor, 100% at the ceiling
Provisional: fitted to a short history, so treat the lines as a first read rather than a projection. No trade is suggested and alerts stay off until there is more data.
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
The lines above are fitted to a short history, which is not a base we will project a published call from. The buy and target below are still this site's read of those lines.
Buy at or below
US$26.49
level as at 17 Sept 2026
Our target
US$29.73
by 16 Dec 2026
Projected move
12.2%
gross, before costs
Price sits between our buy level and our target.
On this stock's own history these rules produced 4 settled calls, of which 0 reached target (0%), with an average best move of 7.4%. See the full record.
- Upper line touches
- 11
- Lower line touches
- 13
- Fit confidence
- 34%
- Fitted
- 16 Sept 2026
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla
- Employees
- 75,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- 57/100
- Profitability
- 41/100
- Financial health
- 43/100
- Cash generation
- 66/100
Key statistics
- Market cap
- US$153.14B
- Enterprise value
- US$215.36B
- Beta
- 0.28
- Avg volume
- 39.98M
- Revenue per share
- 11.18
- Dividend yield
- 6.40%
- 52-week range
- 23.58-28.75
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 35.50
- PEG
- -0.59
- Price / sales
- 2.40
- Price / book
- 1.80
- EV / EBITDA
- 17.06
- Gross margin
- 71.32%
- Operating margin
- 25.08%
- Net margin
- 6.81%
- Current ratio
- 1.27
- Quick ratio
- 0.96
- Debt / equity
- 0.74
- Interest cover
- 5.92
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$62.58B | US$44.01B | US$15.44B | US$7.77B | US$1.36 |
| 2024 | US$63.63B | US$41.85B | US$16.48B | US$8.02B | US$1.41 |
| 2023 | US$59.55B | US$30.34B | US$5.29B | US$2.13B | US$0.37 |
| 2022 | US$100.33B | US$62.09B | US$37.55B | US$31.36B | US$5.47 |
| 2021 | US$81.29B | US$46.88B | US$20.79B | US$22.15B | US$3.88 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$208.16B | US$121.39B | US$86.48B |
| 2024 | US$213.40B | US$124.90B | US$88.20B |
| 2023 | US$226.50B | US$137.21B | US$89.01B |
| 2022 | US$197.21B | US$101.29B | US$95.66B |
| 2021 | US$181.48B | US$104.01B | US$77.20B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$11.71B | US$9.08B | US$7.75B |
| 2024 | US$12.74B | US$9.84B | US$8.05B |
| 2023 | US$8.70B | US$4.79B | US$2.17B |
| 2022 | US$29.27B | US$26.03B | US$31.40B |
| 2021 | US$32.58B | US$29.87B | US$22.46B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$3.12 | US$61.94B | 17 |
| 2026 | US$2.97 | US$62.10B | 14 |
| 2027 | US$2.87 | US$59.49B | 14 |
| 2028 | US$2.46 | US$54.66B | 6 |
| 2029 | US$2.36 | US$52.98B | 3 |
| 2030 | US$2.44 | US$53.37B | 2 |
Analyst view
- Target (mean)
- US$27.38
- Target (high)
- US$31.00
- Target (low)
- US$25.00
- Strong buy
- 0
- Buy
- 15
- Hold
- 23
- Sell
- 1
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.